Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Review Article
Opioid-Induced Hyperalgesia
| Fady Youssef1, Alan Pater2 and Marlene Shehata3* | |
| 1Carleton University, Ottawa, ON, Canada | |
| 2Memorial University of Newfoundland, NL, Canada | |
| 3Marlene Shehata Pharmaceuticals, Ottawa, ON, Canada | |
| Corresponding Author : | Shehata M Clinical Pharmacist Consultant/Cardiovascular Geneticist Marlene Shehata Pharmaceuticals, Ottawa, Ontario, Canada Tel: 613-890-5476 Fax: 347-710-5334 E-mail: marlenefouad@yahoo.com |
| Received March 16, 2015; Accepted May 19, 2015; Published May 21, 2015 | |
| Citation: Youssef F, Pater A, Shehata M (2015) Opioid-Induced Hyperalgesia. J Pain Relief 4:183. doi: 10.4172/2167-0846.1000183 | |
| Copyright: © 2015 Youssef F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Opioid-induced hyperalgesia (OIH) is a state of sensitization of pain receptors caused by opioid use. In OIH, there is a paradoxical response to opioids, in which opioids that are used to produce analgesia will instead induce sensitization to certain painful stimuli. The resulting pain might be similar or different from the original pain for which the opioids were taken. OIH is a characteristic phenomenon that could explain the loss of opioid effectiveness in many patients. The exact molecular mechanism for OIH is not yet fully understood. However, four proposed mechanisms are being considered in the present review to explain OIH including; N-methyl-D-aspartate (NMDA) receptor activation; spinal dynorphin; descending facilitation; and finally decreased reuptake and enhanced nociceptive response. It is important for clinicians to consider OIH in opioid-treated patients, particularly for any new appearance of unexplained pain, or when increasing the opiate dose results in worsening of the pain. OIH is managed by reducing opioid dosage, tapering opiods off, and adding NMDA receptor antagonists.
